MyFinsight
Home
Blog
About
Proceeds from exercise of
warrants
$2,817K
(28070.00%↑ Y/Y)
Proceeds from issuance of
common stock under...
$800K
Net cash provided by
financing activities
$3,613K
(-73.08%↓ Y/Y)
Canceled cashflow
$4K
Net increase
(decrease) in cash and cash...
-$3,055K
(-193.17%↓ Y/Y)
Canceled cashflow
$3,613K
Accrued expenses and
other current...
$1,729K
(396.84%↑ Y/Y)
Stock-based compensation
$436K
(-51.66%↓ Y/Y)
Depreciation and
amortization
$8K
(-86.44%↓ Y/Y)
Change in fair value of
warrant liability
$7K
(100.04%↑ Y/Y)
Transaction costs allocated
to warrant...
$2K
(-99.93%↓ Y/Y)
Proceeds from sale of
common stock,...
-$4K
(-100.03%↓ Y/Y)
Net cash used in
operating activities
-$6,657K
(34.39%↑ Y/Y)
Canceled cashflow
$2,182K
Effect of exchange rate
changes on cash and cash...
-$11K
(-466.67%↓ Y/Y)
Net loss
-$7,635K
(45.76%↑ Y/Y)
Prepaid expenses and
other assets
$816K
(-45.71%↓ Y/Y)
Accounts payable
-$238K
(-115.60%↓ Y/Y)
Operating lease, net
-$150K
(-229.31%↓ Y/Y)
Back
Back
Cash Flow
Moleculin Biotech, Inc. (MBRX)
Moleculin Biotech, Inc. (MBRX)
source: myfinsight.com